~~<i id='2F533472D5'><strike id='2F533472D5'><tt id='2F533472D5'><pre id='2F533472D5'></pre></tt></strike></i>~~

Home» knowledge» focus

focus

author：Wikipedia 2025-10-01 05:50:08 Page View：5

AP/Richard Drew

Johnson & Johnson said Monday that it would purchase Ambrx Biopharma for nearly $2 billion, picking up a company specializing in targeted chemotherapy treatments — one of the hottest areas of cancer drug development.

The deal, disclosed as the biopharma field marked the first day of the annual J.P. Morgan Healthcare Conference, extends a recent spate of pharma acquisitions, contributing to hopes that 2024 could be a better year for the industry.

Under the agreement, J&J will pay $28 per share in cash for Ambrx, roughly a 100% premium to the latter’s recent trading price.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How I helped Pfizer think through the ethics of Viagra
Next article： State Dept. review finds Biden bears some blame for Afghanistan failures

explore

Jerome Adams on the need for new antivirals for Covid

PaxlovidtabletsamplesbeinginspectedinFreiburg,Germany.PfizerviaAPTheU.S.Covid-19Public HealthEmergen

Group behind ProMed defends move to subscription

ProMEDmapScreengrabviaProMEDTheorganizationthatrunsProMed,anearlywarningsystemondiseaseoutbreaks,def

Peter Hotez and the public health issue of online harassment

AdobeFather’sDayweekendwasanythingbutcalmonTwitter,whicheruptedasvaccineexpertPeterHotezwaschallenge

Pharma showers House GOP doctor with campaign cash

Rep.LarryBucshon(R-Ind.)receivedasignificantamountofcampaigndonationsfromthepharmaceuticalindustryin